Cantor on Lyra Therapeutics (LYRA):'Better-Than-Expected BEACON Results Expand Opportunity for LYRA's CRS Platform'
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $15.00 price target on Lyra Therapeutics (NASDAQ: LYRA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
